ARGENX SE

ARGX
Real-time Estimate Quote. Real-time Estimate  - 08/13 03:59:59 pm
200.6EUR +0.85%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. The ability to execute on this focus is enabled by the suite of differentiated technologies. The SIMPLE Antibody? Platform, based on the powerful llama immune system, allows the group to exploit novel and complex targets, and its three antibody engineering technologies are designed to expand the therapeutic index of its product candidates.

Number of employees : 188 people.
Sales per Business
20182019
EUR
(in Million)
%EUR
(in Million)
%
Milestone Payments 11.4453.3% 28.0940.2%
Upfront Payments 8.6440.2% 22.3632%
Research and Development Service Fees (FTE) 1.416.5% 19.3427.7%
Sales per region
2019
EUR
(in Million)
%
Switzerland 40.5958.2%
Luxembourg 27.2639.1%
Belgium 1.502.1%
Denmark 0.4360.6%
Netherlands --
Managers
Name Title
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
David L. Lacey Independent Non-Executive Director
Werner Lanthaler Vice Chairman
Joseph Donald deBethizy Independent Non-Executive Director
Pamela M. Klein Independent Non-Executive Director
Shareholders
Name Equities %
Fidelity Management & Research Co. LLC 4,279,107 9.10%
Johnson & Johnson Innovation JJDC, Inc. 1,766,899 3.76%
Wellington Management Co. LLP 1,540,070 3.28%
Federated Global Investment Management Corp. 1,522,200 3.24%
RTW Investments LP 1,436,705 3.06%
The Vanguard Group, Inc. 1,403,916 2.99%
Baillie Gifford & Co. 1,401,085 2.98%
Bellevue Asset Management AG 930,000 1.98%
Norges Bank Investment Management 787,039 1.67%
BlackRock Fund Advisors 452,747 0.96%
Company contact information
5 Willemstraat
NL-4811 AH Breda
Netherlands

Phone : +31 (0) 763 030 488
Fax : +31
Internet : http://www.argen-x.com
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Next 150, Next Biotech, PEA
Stock Exchange Codes
- ISIN Code :  NL0010832176
- Reuters Code :  ARGX.AS
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ARGENX SE47.90%11 049
GILEAD SCIENCES, INC.5.94%86 319
VERTEX PHARMACEUTICALS23.70%70 548
REGENERON PHARMACEUTICALS63.08%64 438
WUXI APPTEC CO., LTD.62.81%37 073
GENMAB A/S53.09%23 475
BEIGENE, LTD.28.64%19 295
BIONTECH SE103.98%16 460
HUALAN BIOLOGICAL ENGINEERING INC.99.86%14 564
SAREPTA THERAPEUTICS, INC.22.44%12 404
ARGENX SE38.51%11 049
NEUROCRINE BIOSCIENCES, INC.6.24%10 653
ASCENDIS PHARMA A/S1.35%7 502
EXELIXIS, INC.24.06%6 755
BIOCON LIMITED33.90%6 289
ZAI LAB LIMITED91.51%5 971
MIRATI THERAPEUTICS, INC.2.12%5 874
PEPTIDREAM INC.-16.52%5 549
ACCELERON PHARMA INC.73.90%5 530
MYOKARDIA, INC.39.29%5 383
ULTRAGENYX PHARMACEUTICAL INC.96.23%5 077